Switzerland

Switzerland's psychedelic history starts with unusually strong scientific roots. Albert Hofmann first synthesised LSD at Sandoz in Basel in 1938 and identified its psychoactive effects in 1943. Sandoz then distributed LSD for psychiatric research under Delysid, making Basel central to the early global research period. #

That early openness narrowed as international and domestic controls hardened from the late 1960s onward. LSD, psilocybin, MDMA and related substances moved into prohibited or highly controlled categories, and clinical work became rare outside tightly approved research. # #

Modern Swiss work restarted through clinical pharmacology and small patient studies rather than commercial roll-out. Basel has been especially important for controlled human pharmacology and LSD or psilocybin studies, while Zurich has contributed neuroimaging and translational psychiatry work. # # #

From 2014, FOPH began granting case-by-case permissions for limited medical use of substances such as LSD and MDMA, later including psilocybin. That created a distinct Swiss route: physician-led, patient-specific exceptions for severe cases after other options have been exhausted, rather than an authorised psychedelic medicine market. # #

The 2022 medical-cannabis reform is relevant as a contrast. Cannabis medicines no longer require the same FOPH exception permission, but no comparable broad reform has happened for LSD, psilocybin, MDMA, DMT or mescaline. The 2025 BAG expert report therefore matters because it takes stock of a growing but still exceptional practice. # #

The Basel-Zurich corridor is Switzerland's most important psychedelic research axis. Basel carries the strongest historical and pharmacology identity, from Sandoz and Hofmann through to modern LSD, psilocybin, MDMA and DMT studies. # # #

Zurich adds neuroimaging, systems neuroscience and translational psychiatry strength. Its contribution is important because it links acute psychedelic effects to brain networks, cognition and clinical mechanisms rather than only to access policy. #

This corridor also matters operationally. Switzerland's limited medical use model depends on specialist physicians, institutional ethics, controlled supply and careful follow-up. Basel and Zurich have the clinical and scientific infrastructure most suited to that model. # #

The corridor is not the whole country, especially now that Spravato reimbursement is tied to a national list of approved psychiatric centres. But for psychedelic research and policy interpretation, Basel and Zurich remain the reference points. # #

Switzerland's likely direction is controlled medical expansion inside existing institutions rather than consumer legalisation. The FOPH exception model already allows carefully selected cases, so policy pressure is likely to focus on standards, physician experience, indications, reporting and payer evidence. # #

The main reimbursement question is whether classical psychedelics can move beyond self-pay exceptional care. For now, compulsory insurance has a clear route for Spravato but not for FOPH-permitted LSD, psilocybin or MDMA treatment. Stronger cost-effectiveness and service-delivery evidence would be needed before that changes. # # #

Switzerland should remain one of Europe's most important research countries because it has both historical depth and active clinical pharmacology capacity. The limiting factor is not scientific credibility; it is whether exceptional access can scale without losing clinical safeguards. # # #